Advances in Medical Management of Early Stage and Advanced Breast Cancer: 2015
Author:
Publisher
Elsevier BV
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology
Reference65 articles.
1. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial;Fisher;J Natl Cancer Inst,2001
2. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer;Goss;N Engl J Med,2003
3. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: Analyses adjusting for treatment crossover;Jin;J Clin Oncol,2012
4. Impact of premenopausal status at breast cancer diagnosis in women entered on the placebo-controlled NCIC CTG MA17 trial of extended adjuvant letrozole;Goss;Ann Oncol,2013
5. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial;Davies;Lancet,2013
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. CYP2S1 and CYP2W1 expression is associated with patient survival in breast cancer;The Journal of Pathology: Clinical Research;2022-07-28
2. GSTP1 c.313A > G mutation is an independent risk factor for neutropenia hematotoxicity induced by anthracycline-/paclitaxel-based chemotherapy in breast cancer patients;World Journal of Surgical Oncology;2022-06-22
3. Therapeutische Grundlagen in der gynäkologischen Onkologie;Facharztwissen Gynäkologie;2021
4. Beclin1 inhibition enhances paclitaxel‑mediated cytotoxicity in breast cancer in�vitro and in�vivo;International Journal of Molecular Medicine;2019-02-01
5. Cumulative receiver operating characteristics for analyzing interaction between tissue visfatin and clinicopathologic factors in breast cancer progression;Cancer Cell International;2018-02-09
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3